TY - JOUR T1 - IKBKB reduces huntingtin aggregation by phosphorylating Serine 13 via a non-canonical IKK pathway JF - bioRxiv DO - 10.1101/2022.12.05.519070 SP - 2022.12.05.519070 AU - Cristina Cariulo AU - Paola Martufi AU - Margherita Verani AU - Leticia Toledo-Sherman AU - Ramee Lee AU - Celia Dominguez AU - Lara Petricca AU - Andrea Caricasole Y1 - 2022/01/01 UR - http://biorxiv.org/content/early/2022/12/05/2022.12.05.519070.abstract N2 - N-terminal phosphorylation at residues T3 and S13 is believed to have important beneficial implications for the biological and pathological properties of mutant huntingtin, where IKBKB was identified as a candidate regulator of huntingtin N-terminal phosphorylation. The paucity of mechanistic information on IKK pathways, together with the lack of sensitive methods to quantify endogenous huntingtin phosphorylation, prevented detailed study of the role of IKBKB in Huntington’s disease. Using novel ultrasensitive assays, we demonstrate that IKBKB can regulate endogenous S13 huntingtin phosphorylation in a manner dependent on its kinase activity and known regulators. We found that the ability of IKBKB to phosphorylate endogenous huntingtin S13 is mediated through a non-canonical IRF3-mediated IKK-pathway, distinct from the established involvement of IKBKB in mutant huntingtin’s pathological mechanisms mediated via the canonical pathway. Furthermore, increased huntingtin S13 phosphorylation by IKBKB resulted in decreased aggregation of mutant huntingtin in cells, again dependent on its kinase activity. These findings point to a non-canonical IKK-pathway linking S13 huntingtin phosphorylation to the pathological properties of mutant huntingtin aggregation, thought to be significant to Huntington’s disease. ER -